Put companies on watchlist
MEDICLIN AG
ISIN: DE0006595101
WKN: 659510
Curious about what AI knows about Mediclin? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

MEDICLIN AG · ISIN: DE0006595101 · EQS - Company News (58 News)
Country: Germany · Primary market: Germany · EQS NID: 2150686
04 June 2025 01:27PM

Annual General Meeting approves all proposed resolutions


EQS-News: MEDICLIN AG / Key word(s): AGM/EGM
MEDICLIN AG: Annual General Meeting approves all proposed resolutions

04.06.2025 / 13:27 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, 4 June 2025

MEDICLIN AG: Annual General Meeting approves all proposed resolutions
 
Offenburg, 4 June 2024: MEDICLIN Aktiengesellschaft (MEDICLIN) held its Annual General Meeting as a virtual Annual General Meeting on Wednesday, 4 June.

The Executive Board was extremely positive about the 2024 financial year, with the post-acute segment in particular, which reflects the company's rehabilitation expertise, making considerable progress. This momentum is to be continued in the current year.

Successful despite changes in the healthcare market

Dr Joachim Ramming, CEO, praised the financial results for 2024 as a milestone in the company's history. "We have not only achieved the highest sales, but also the strongest EBIT in our history," emphasised the CEO in his review. At the same time, he referred to the far-reaching changes in the healthcare market: increasing outpatient care, digital care models and an intensified shortage of specialists. These trends call for agile action and targeted investments. "Thanks to our forward-looking projects MEDICLIN HOME, MEDICLIN DIRECT and MEDICLIN CAMPUS, we are utilising change as an opportunity and are well positioned for the future," he commented.

Information on the Annual General Meeting

All resolutions proposed by the management were approved by a majority. 91.42% of the share capital was represented at the Annual General Meeting. The resolution on the appropriation of net retained profits and the distribution of a dividend was approved by a majority of 99.67%. In addition to the discharge of the Executive Board and Supervisory Board with majorities of 99.20% and 99.20% respectively, the re-election of two Supervisory Board members was also on the agenda. The previous Chairman of the Supervisory Board, Dr Jan Liersch, and Mr Marco Walker, who was already a member of the Supervisory Board, were re-elected to the Board. KPMG AG Wirtschaftsprüfungsgesellschaft was appointed as auditor and group auditor for the 2025 financial year with a majority of 99.20%. The Annual General Meeting confirmed the remuneration of the Supervisory Board with a majority of 99.99%.  

All voting results can be viewed under the following link.

MEDICLIN will publish its interim report for the first half of 2025 on 31 July.


For further information:

MEDICLIN Aktiengesellschaft
Okenstrasse 27
77652 Offenburg

Investor Relations
Ender Gülcan
Phone: 0781/488-326
ender.guelcan@mediclin.de


Public Relations
Dr Janina Lossen
Phone: 0781/488-180
janina.lossen@mediclin.de

www.mediclin.de


About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 31 clinics, six care facilities and ten medical care centers. The group has around 8,200 beds/care places and employs around 9,900 people.
In a strong network, MEDICLIN offers the patients integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group


 


04.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDICLIN AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2150686

 
End of News EQS News Service

2150686  04.06.2025 CET/CEST

Visual performance / price development - MEDICLIN AG
Smart analysis and research tools can be found here.
MIC: XETR

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.